Efficacy of low-molecular-weight heparin in acute coronary syndromes

American Heart Journal

Volumn 139, Issue 2 II, 2000, Pages

  Wallentin, L ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; TIROFIBAN;

ANTICOAGULANT THERAPY; CAUSE OF DEATH; CONFERENCE PAPER; DOSE RESPONSE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; META ANALYSIS; OUTPATIENT; PRIORITY JOURNAL; RISK FACTOR; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

EID: 0033981762     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2000.103744     Document Type: Conference Paper

References (7)

1. The PRISM-PLUS investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med 1998;338:1488-97.
2. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecularweight heparin and with a direct thrombin inhibitor. Circulation 1998;97:251-6.
3. Wallentin L. Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes. Eur Heart J 1996;17: 1470-6.
4. Lindahl B, Venge P, Wallentin LFRISC. Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. J Am Coll Cardiol 1997;29:43-8.
5. Antman EM, for the Thrombolysis in Myocardial Infarction (TIMI) 11B trial investigators. TIMI-11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial. Rationale, study design, and methods. Am Heart J 1998;135:S353-S360.
6. Wallentin L, Husted S, Kontny F, Swahn E. Long-term low-molecularweight heparin (fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study). Am J Cardiol 1997;80:61E-63E.
7. Frostfeldt G, Ahlberg G, Gustafsson G, et al. Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction-a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II). J Am Coll Cardiol 1999;33: 627-33.